Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
TerpenoidΔ-11-Tetrahydrocannabinol
Δ-11-THC (Δ-9,11-tetrahydrocannabinol) is a trace cannabinoid of the classical cannabinoid class. It is a positional isomer of Δ9-THC, distinguished by an exocyclic double bond that sharply reduces potency.[1] This structural change weakly activates cannabinoid receptors in the brain, producing dramatically diminished effects compared to standard THC.
Δ-11-THC (Δ-9,11-tetrahydrocannabinol) is a naturally-occurring trace cannabinoid of the classical cannabinoid class. It is a positional isomer of Δ9-THC, distinguished by an exocyclic double bond that sharply reduces potency.[1] Δ-11-THC is a weak partial agonist at CB1 receptors, producing greatly diminished cannabimimetic activity in primates.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
TerpenoidSynthesized in 1971 as a research tool for studying how double bond position affects cannabinoid activity,[2] it served through the 1980s as a pharmacological benchmark — an "inactive" reference compound rather than a drug of interest.[3] After 2021, it entered the US consumer market as a semi-synthetic hemp product sold as "Delta-11 THC," exploiting regulatory ambiguity created by the 2018 Farm Bill.[4]
Subjective effects include mild relaxation, possible mood shift, and slight cognitive blunting — though no controlled human study has confirmed the compound is psychoactive. The experience, if it occurs at all, is weaker than even Δ8-THC — closer to the floor of the cannabinoid range than a recognizable high. Consumer reports exist but cannot be verified for compound identity, dose, or product purity.
No dependence data exist; animal studies suggest lower acute toxicity than Δ9-THC,[5] but no safe dose has been established for humans. The dominant risk is the unregulated market — products are untested for purity, and "3× stronger than Δ9-THC" marketing claims almost certainly reflect confusion with a different, genuinely potent compound. Everything known comes from animal studies; no controlled human data exist.
History[edit]
Discovery
Δ-9,11-THC was synthesized in 1971 by researchers at the Research Triangle Institute[2][6] as a tool compound for studying how double bond position influences cannabinoid activity. The exocyclic bond placement was expected to reduce biological activity relative to Δ9-THC — a prediction the compound largely confirmed.
Research trajectory
Through the late 1980s and early 1990s, it served as a pharmacological benchmark. Beardsley and colleagues showed in 1987 that it produced cannabimimetic effects in mice but was essentially inactive in rhesus monkeys — and that pretreatment attenuated Δ9-THC's effects in primates, suggesting functional antagonism.[5] It was classified as an "inactive cannabinoid" based on ring geometry,[3] though later work concluded it was "more potent than previous reports indicated".[7]
Market emergence
The 2018 US Farm Bill legalized hemp-derived cannabinoids containing ≤0.3% Δ9-THC, creating a commercial pathway for semi-synthetic cannabinoids made by isomerizing hemp-derived CBD.[4][8] Δ-9,11-THC entered this market around 2021–2023 as "Delta-11 THC," sold in vape cartridges, gummies, and tinctures.
The name "Delta-11 THC" is a retail invention. Its systematic designation is Δ-9,11-trans-tetrahydrocannabinol; the alternate name exo-THC references the exocyclic bond position.[1] Marketing claims of "up to 3× stronger than Δ9-THC" almost certainly arise from confusion with 11-hydroxy-Δ9-THC — a structurally distinct hepatic metabolite of Δ9-THC that is genuinely more potent. No published data support these potency claims.
Chemistry[edit]
Structural class
Δ-9,11-THC belongs to the classical cannabinoid family — tricyclic compounds built on a dibenzopyran core. It shares the molecular formula C₂₁H₃₀O₂ with Δ9-THC and Δ8-THC, differing only in where the double bond sits. Rather than the endocyclic bond of Δ9-THC, Δ-9,11-THC carries an exocyclic bond projecting outward from the ring at C9.[1]
| Molecular formula | C₂₁H₃₀O₂ |
| Molecular weight | 314.46 g/mol |
Structure and activity
This exocyclic position forces the molecule's carbocyclic ring into a chair conformation — rather than the half-chair adopted by pharmacologically active cannabinoids.[3] The geometric mismatch misaligns molecular features thought to be essential for cannabinoid receptor engagement.[1] Only the (−)-trans enantiomer has been reported in the literature.[2]
Pharmacology[edit]
Mechanism of action
Δ-9,11-THC is classified as a weak CB1 partial agonist. The exocyclic double bond forces the ring into a chair geometry rather than the half-chair of active cannabinoids like Δ9-THC,[3] misaligning features needed for receptor engagement. No binding affinity values have been published for this compound.safety citation needed
Species-dependent activity
Its pharmacology is profoundly species-dependent.[5] In mice it produced cannabimimetic effects — reduced movement, hypothermia, analgesia. In rhesus monkeys it was essentially inactive, and pretreatment blocked Δ9-THC's effects, suggesting functional antagonism. Drug discrimination studies confirmed Δ9-THC-like responding in rodents and monkeys but at reduced potency.[9]
Pharmacokinetics
No human pharmacokinetic data exist. Animal microsome studies identified 11 metabolites through three pathways — side-chain hydroxylation, ring hydroxylation, and an epoxide-diol route[10] — with the pattern varying dramatically by species, making human predictions unreliable.[10]
Neuroscience[edit]
Where it acts
No neuroimaging or direct brain data exist for Δ-9,11-THC.inferred CB1 receptors concentrate in the cortex, hippocampus, basal ganglia, cerebellum, and amygdala — regions governing memory, coordination, and emotion. If Δ-9,11-THC engages these receptors in humans (not established), it would produce attenuated versions of the memory disruption and mood changes characteristic of Δ9-THC.
Why it matters
The sharp species gap — active in mice, negligible in primates — is unusual for a simple positional isomer. No molecular investigation has been conducted into why it occurs. The pattern raises broader questions about how well rodent cannabinoid models predict human responses.
- Does Δ-9,11-THC produce psychoactive effects in humans at achievable doses? The primate data suggest minimal CB1 engagement, but no controlled human study has been conducted.[5]
- Does it function as a partial antagonist in humans? Pretreatment attenuated Δ9-THC effects in monkeys[5] but not in a drug discrimination paradigm[9] — whether it modulates Δ9-THC effects in human co-users is unknown.
- What is the human metabolite profile? With 11 metabolites and profound interspecies variation identified in animals,[10] the human profile cannot be predicted.
Subjective Effects[edit]
If Δ-9,11-THC produces effects in humans at all — which primate pharmacology suggests is unlikely at typical doses — they resemble a mild, attenuated cannabinoid state: slight relaxation, possible mood shift, and a faint softening of mental sharpness. It does not produce the euphoria, perceptual alteration, or appetite stimulation of full cannabinoid agonism.
Among THC isomers, Δ-9,11-THC sits at the bottom of the activity range — weaker than Δ8-THC, which is itself less potent than Δ9-THC. Consumer reports describe cannabinoid-like effects, but these cannot be verified for compound identity or product purity, making reliable comparison impossible.
First synthesized in 1971 at the Research Triangle Institute as a structural probe for cannabinoid structure–activity relationships,[3] Δ-9,11-THC served through the 1980s primarily as an "inactive" benchmark in pharmacological comparisons.[4] After 2021 it entered the US consumer market as a semi-synthetic hemp derivative sold under the retail name "Delta-11 THC," exploiting regulatory ambiguity created by the 2018 Farm Bill.[5] No clinical trials have been registered.
Subjective effects — if any occur — are expected to include mild relaxation, possible anxiolysis, and reduced cognitive sharpness, though no controlled human study has confirmed psychoactivity. The experience, if present, would resemble a substantially attenuated version of the Δ9-THC experience — weaker than even Δ8-THC based on available animal pharmacology. Unsought effects have not been characterized; consumer self-reports are unverified for compound identity, dose, and product purity.
No dependence data exist, and no lethal dose has been established — lethality in mice required doses above those needed for Δ9-THC,[2] and adverse cardiovascular interactions with epinephrine have been documented in rats.[6] The primary risk is the unregulated market: products are untested for purity, and marketing claims that Δ-11-THC is "3× stronger than Δ9-THC" almost certainly reflect confusion with 11-hydroxy-Δ9-THC, a genuinely potent hepatic metabolite. The evidence base is critically deficient — no controlled human data exist, and the pharmacological profile rests entirely on animal studies from the 1980s and 1990s.
History[edit]
Discovery
Synthesized in 1971 by researchers at the Research Triangle Institute in North Carolina,[3][7] Δ-9,11-THC was created as a tool compound for investigating how double bond position influences cannabinoid activity. The exocyclic bond placement was expected to diminish biological activity relative to Δ9-THC and Δ8-THC — a prediction the compound largely confirmed.
Research trajectory
Through the late 1980s and early 1990s, Δ-9,11-THC served as a pharmacological benchmark. Beardsley and colleagues demonstrated in 1987 that it produced cannabimimetic effects in mice but was essentially inactive in rhesus monkeys — and that pretreatment attenuated the effects of Δ9-THC in primates, suggesting functional antagonism.[2] Concurrently, conformational analysis classified it as an "inactive cannabinoid" based on its ring geometry,[4] though Compton et al. later concluded it was "more potent than previous reports indicated".[8]
Market emergence
The 2018 US Farm Bill legalized hemp-derived cannabinoids containing ≤0.3% Δ9-THC by dry weight, inadvertently creating a commercial pathway for semi-synthetic cannabinoids produced by isomerizing hemp-derived CBD.[5][9] Following the commercial success of Δ8-THC and HHC, Δ-9,11-THC entered the consumer market around 2021–2023 under the retail name "Delta-11 THC," sold in vape cartridges, gummies, and tinctures. It remains a minor but growing segment of the unregulated cannabinoid market.[5]
The name "Delta-11 THC" is a retail invention. The compound's systematic designation is Δ-9,11-trans-tetrahydrocannabinol, reflecting the double bond between carbons 9 and 11; its alternate name exo-THC references the exocyclic position of that bond.[1] Marketing claims that the compound is "up to 3× stronger than Δ9-THC" almost certainly arise from confusion with 11-hydroxy-Δ9-THC (11-OH-THC), a structurally distinct hepatic metabolite of Δ9-THC that is genuinely more potent than its parent compound. No published data support the potency claims attached to Δ-9,11-THC products.
Chemistry[edit]
Structural class
Δ-9,11-tetrahydrocannabinol belongs to the classical cannabinoid family — tricyclic terpenophenols built on a dibenzopyran core. It shares the molecular formula C₂₁H₃₀O₂ with Δ9-THC, Δ8-THC, and Δ10-THC, differing only in double bond placement.
Where Δ9-THC carries an endocyclic double bond between C9 and C10 within the cyclohexene ring, Δ-9,11-THC bears an exocyclic methylidene (=CH₂) group at C9, projecting the double bond outward from the ring system between C9 and C11.[1] The molecule retains the phenolic hydroxyl at C1 and n-pentyl side chain at C3 common to all classical phytocannabinoids.
| Molecular formula | C₂₁H₃₀O₂ |
| Molecular weight | 314.46 g/mol |
Stereochemistry
Only the (6aR,10aR) enantiomer — the (−)-trans form — has been reported in the literature.[3] The two chirality centers at the ring junction share the same absolute configuration as naturally occurring (−)-Δ9-THC.
Structure–activity relationships
The exocyclic double bond has significant consequences for ring geometry and receptor engagement. Molecular mechanics calculations determined that the carbocyclic ring of Δ-9,11-THC adopts a chair conformation, in contrast to the half-chair of pharmacologically active Δ9-THC.[4] This conformational difference misaligns the C9 substituent relative to the phenolic hydroxyl — a spatial relationship proposed as critical for CB1 recognition.
NMR analysis confirmed the distinct solution conformation of Δ-9,11-THC relative to Δ9-THC, characterizing the compound as "biologically inactive" on structural grounds.[1]
Physical properties
No published data on melting point, solubility, or solid-state stability specific to Δ-9,11-THC exist. By structural analogy to Δ9-THC — a viscous resinous oil at room temperature, sparingly soluble in water, freely soluble in ethanol and nonpolar solvents — similar physical properties are expected but remain unconfirmed.inferred
Pharmacology[edit]
Mechanism of action
Δ-9,11-THC is classified as a weak CB1 partial agonist, though this designation substantially overstates its functional potency. No binding affinity values have been published for this compound at any receptor target.safety citation needed
The structural basis for its reduced activity lies in ring conformation: the exocyclic double bond forces the carbocyclic ring into a chair geometry rather than the half-chair adopted by active cannabinoids like Δ9-THC.[4] This misaligns the molecular features proposed as essential for CB1 receptor engagement.
Compton et al. partially challenged the "inactive" classification, concluding that Δ-9,11-THC "is more potent than previous reports indicated" based on receptor binding assays, while confirming the importance of the phenolic hydroxyl for receptor recognition.[8]
Species-dependent activity
The most striking feature of Δ-9,11-THC's pharmacology is its profoundly species-dependent profile.[2]
In mice, the compound produced classical cannabimimetic effects — hypothermia, analgesia, reduced locomotion, and lethality — qualitatively comparable to Δ9-THC but at higher doses.
In dogs, it failed to produce canonical cannabimimetic signs. Most animals showed dose-independent sedation that appeared earlier and dissipated faster than Δ9-THC effects — described as "noncannabimimetic-like".[2]
In rhesus monkeys, the compound was "perhaps devoid of cannabimimetic effects," producing no ptosis, sedation, or ataxia. It was 8- to 100-fold less potent than Δ9-THC for suppressing trained behavior. Pretreatment with Δ-9,11-THC increased the doses of Δ9-THC required to produce effects in monkeys — suggesting functional antagonism. In mice and dogs, however, pretreatment enhanced Δ9-THC effects.[2]
Drug discrimination
When rats and monkeys trained to discriminate Δ9-THC were tested, Δ-9,11-THC produced Δ9-THC-appropriate responding in both species but with reduced potency.[10] The potency difference was greater in monkeys than in rats. However, Δ-9,11-THC failed to block the Δ9-THC cue in either species, leading the authors to conclude it "is devoid of antagonistic properties in the drug discrimination paradigm".[10]
Cardiovascular effects
In anesthetized rats, Δ-9,11-THC produced blood pressure reductions approximately 8-fold less potently than Δ9-THC.[6] Both compounds potentiated the blood pressure and heart rate effects of epinephrine and produced epinephrine-induced irregular heart rhythms not observed with vehicle alone.[6]
Pharmacokinetics
No human pharmacokinetic data exist. Bioavailability, peak concentration, half-life, and metabolic pathways have not been characterized in humans.
Harvey and Brown incubated Δ-9,11-THC with liver microsomes from seven animal species and identified 11 metabolites through three principal pathways: hydroxylation along the pentyl side chain, hydroxylation at the C-8 ring position, and an epoxide-diol pathway.[11] Metabolism was markedly species-dependent — mice favored ring hydroxylation, guinea pigs favored side-chain hydroxylation, and rabbits predominantly formed epoxide-diol products.[11]
The authors concluded that "the results emphasise the need to make appropriate choices of animal models for metabolic and toxicological studies in humans".[11]
Neuroscience[edit]
Where it acts
No neuroimaging, electrophysiology, or direct neural data exist for Δ-9,11-THC. All inference derives from its classification as a weak CB1 partial agonist.inferred
CB1 receptors concentrate on presynaptic terminals throughout the cortex, hippocampus, basal ganglia, cerebellum, and amygdala. If Δ-9,11-THC engages these receptors in humans — which is not established — it would modulate glutamate and GABA release through retrograde endocannabinoid signaling, producing attenuated versions of the memory disruption, motor coordination changes, and emotional modulation characteristic of Δ9-THC.
Why it matters
The species-dependent activity profile — active in mice, negligible in primates — is unusually sharp for a simple positional isomer. This divergence may reflect differences in the CB1 receptor binding pocket or downstream signaling efficiency between species, but no molecular investigation has been conducted. The phenomenon raises broader questions about how well rodent cannabinoid models predict primate and human responses.
- Does Δ-9,11-THC produce psychoactive effects in humans at achievable doses? The primate data suggest minimal CB1 engagement, but no controlled human study has been conducted.[2]
- Does it function as a partial antagonist in humans? Pretreatment attenuated Δ9-THC effects in monkeys[2] but not in a drug discrimination paradigm[10] — whether it modulates Δ9-THC effects in human co-users is unknown.
- What is the human metabolite profile? With 11 metabolites and profound interspecies variation identified in animals,[11] the human profile cannot be predicted.
Subjective Effects[edit]
The subjective effects of Δ-9,11-THC in humans remain uncharacterized in any controlled setting. Whether the compound produces perceptible psychoactivity through commercial products is itself an open question — primate pharmacology suggests negligible CB1 engagement at doses well above those effective in rodents. If effects occur, the experience would be expected to resemble a substantially muted cannabinoid state: mild relaxation and possible mood shift without the robust euphoria, perceptual alteration, or appetite stimulation characteristic of full CB1 agonism.
Consumer self-reports describe effects qualitatively similar to other cannabinoids, but these accounts are unverified for compound identity, dose, and product purity. Δ-9,11-THC should not be compared to Δ8-THC in potency — published data suggest it is weaker still, and its effects more closely resemble the floor of the cannabinoid dose-response curve than a distinct experiential profile.
Effect Grid
No common dose range has been established for Δ-9,11-THC in humans. No controlled human administration study has been conducted, and the compound's dose-response curve has not been characterized in any species for subjective endpoints.
If common-dose effects occur, they would be expected to resemble a substantially attenuated Δ9-THC experience — mild relaxation, possible anxiety suppression, reduced cognitive sharpness, and slight motor control impairment. The compound is unlikely to produce the robust euphoria or perceptual alteration characteristic of full CB1 agonist doses.
Product purity cannot be assumed in the unregulated semi-synthetic market. Reported effects may reflect contaminants or co-occurring cannabinoids rather than Δ-9,11-THC itself.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Spatial disorientation · Taste enhancement · Touch enhancement · Vestibular distortion · Visual acuity suppression · Olfactory enhancement · Auditory distortion · Auditory misinterpretation · Brightness alteration · Peripheral vision distortion · Visual haze / noise · After-images · Light sensitivity · Tracers · Visual breathing · Visual drifting · Visual acuity enhancement · Visual processing suppression
Spatial disorientation · Taste enhancement · Touch enhancement · Vestibular distortion · Visual acuity suppression · Olfactory enhancement · Auditory distortion · Auditory misinterpretation · Brightness alteration · Peripheral vision distortion · Visual haze / noise · After-images · Light sensitivity · Tracers · Visual breathing · Visual drifting · Visual acuity enhancement · Visual processing suppression
Heart rate perception changes · Laughter fits · Muscle relaxation · Pain suppression · Sedation · Appetite enhancement · Bodily heaviness · Dizziness · Nausea suppression · Physical fatigue · Watery eyes · Body schema distortion · Spontaneous body sensations · Tactile euphoria · Bodily pressures · Breathing alteration · Dehydration sensation · Nausea · Restlessness · Stimulation · Constipation · Tingling / electric sensations · Vibrations / buzzing · Bodily dissociation
Sedation · Appetite enhancement · Bodily heaviness · Dizziness · Nausea suppression · Physical fatigue · Watery eyes · Body schema distortion · Spontaneous body sensations · Tactile euphoria · Bodily pressures · Breathing alteration · Dehydration sensation · Nausea · Restlessness · Stimulation · Constipation · Tingling / electric sensations · Vibrations / buzzing · Bodily dissociation
Cognitive euphoria · Cognitive fatigue · Focus suppression · Immersion enhancement · Information processing suppression · Memory fragmentation · Novelty enhancement · Thought connectivity · Thought disorganization · Humor enhancement · Analysis suppression · Conceptual thinking · Confusion · Creativity enhancement · Introspection enhancement · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought acceleration · Thought deceleration · Thought loops · Cognitive dysphoria · Cognitive flexibility · Compulsive redosing urge · Increased nature relatedness · Memory replays · Synchronicity · Amnesia
Immersion enhancement · Information processing suppression · Memory fragmentation · Novelty enhancement · Thought connectivity · Thought disorganization · Humor enhancement · Analysis suppression · Conceptual thinking · Confusion · Creativity enhancement · Introspection enhancement · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Thought acceleration · Thought deceleration · Thought loops · Cognitive dysphoria · Cognitive flexibility · Compulsive redosing urge · Increased nature relatedness · Memory replays · Synchronicity · Amnesia
Emotional lability · Dysphoria · Empathy enhancement · Simultaneous emotions
Depersonalization · Disinhibition · Social connection · Sociability enhancement · Trust enhancement · Flow state · Cognitive disconnection
Trust enhancement · Flow state · Cognitive disconnection
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- No data
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- 3 weeks
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Negligible
- Dose escalation
- Low
- Cross-tol.
- Δ9-THC · Δ8-THC · other CB1 agonists
Toxicity
Acute toxicity
No controlled toxicity data exist for Δ-9,11-THC in humans.safety citation needed In mice, the compound caused death at higher doses than Δ9-THC — qualitatively similar toxicity but reduced in potency.[5]
Cardiovascular effects
In anesthetized rats, Δ-9,11-THC reduced blood pressure approximately 8-fold less potently than Δ9-THC and amplified blood pressure and heart rate responses to epinephrine.[11] Both compounds triggered irregular heart rhythms not seen with vehicle alone.[11]
Product safety
Δ-9,11-THC is sold only in unregulated semi-synthetic products. Commercial preparations contain multiple coexisting cannabinoids,[4] and consumers cannot assume accurate labeling, purity, or absence of synthesis byproducts.
Psychological risks
No human data exist on psychological risks specific to Δ-9,11-THC.inferred If the compound is psychoactive — which is unconfirmed — the risk profile would resemble other CB1 agonists at reduced potency: acute anxiety, paranoia, and transient perceptual disruption at high doses.
Users who believe they are taking a "3× stronger" compound may dose aggressively, exposing themselves to unexpected effects from whatever the product actually contains.
Tolerance and dependence
No data exist on tolerance, dependence, or withdrawal for Δ-9,11-THC.inferred Given its weak CB1 activity, abuse liability is expected to be lower than Δ9-THC — but this is structural inference without direct evidence.
Drug Interactions
Sympathomimetics / epinephrine: Δ-9,11-THC potentiated epinephrine-induced blood pressure spikes and irregular heart rhythms in anesthetized rats.[11] Whether this extends to humans is unknown but warrants caution.
Δ9-THC: The interaction is species-dependent. Pretreatment attenuated Δ9-THC effects in rhesus monkeys but enhanced them in mice and dogs.[5] The clinical implication for human co-use is unknown.
CYP-mediated interactions: No enzyme inhibition or induction data exist.inferred Similar interactions to Δ9-THC are plausible but unconfirmed.
Contraindications
4 knownNo substance-specific contraindication data exist.inferred The following are inferred from class-level cannabinoid pharmacology and animal data:
- Cardiovascular conditions: The epinephrine-potentiating effect documented in rats[11] suggests caution for those with pre-existing heart conditions, irregular heart rhythms, or concurrent use of sympathomimetic medications.
- Psychotic disorders: CB1 agonism is associated with worsening psychotic symptoms. Even weak CB1 activity cannot exclude this risk.
- Pregnancy and lactation: No reproductive toxicity data exist. Cannabinoids as a class cross the placental barrier and are excreted in breast milk.
Harm Reduction[edit]
Forms & Identification
Δ-9,11-THC is sold exclusively as a semi-synthetic product — vape cartridges, gummies, and tinctures made by isomerizing hemp-derived CBD. No standardized pharmaceutical preparation exists. The primary identification challenge is verifying that products labeled "Delta-11 THC" actually contain Δ-9,11-THC rather than other cannabinoids or synthesis byproducts.
Standard cannabinoid reagent tests cannot distinguish between THC isomers. Mass spectrometry is the only reliable method for confirming compound identity.[4] Without third-party testing results from the manufacturer, the contents should be considered unverified.
Guidelines
- Start with the smallest available dose and wait at least two hours before redosing — onset and duration are uncharacterized.
- Do not rely on marketing potency claims. Assertions that Δ-11-THC is "3× stronger than Δ9-THC" are unsupported and likely reflect confusion with a different compound.
- Avoid combining with other cannabinoids, alcohol, or sedatives until individual response is understood.
- Do not drive or operate machinery.
- Purchase only from manufacturers who provide third-party certificates of analysis showing cannabinoid composition and contaminant testing.
Set & Setting
The near-complete absence of human data means every use of Δ-9,11-THC products is an encounter with an unknown compound. A familiar, comfortable environment and an unimpaired companion are prudent. Effects, if any, are expected to resemble mild cannabinoid intoxication, but product composition is unpredictable.
Aftercare & integration. Δ-9,11-THC is not expected to produce experiences requiring formal integration. If unexpected or uncomfortable effects occurred — particularly anxiety or confusion — allow adequate rest, hydrate, eat light meals, and avoid additional substance use for at least 24 hours. If distressing psychological effects persist beyond a day, consult a healthcare professional.
Recovery & Support
No dependence syndrome has been documented for Δ-9,11-THC specifically. Individuals concerned about patterns of cannabinoid use more broadly may benefit from SAMHSA's National Helpline (1-800-662-4357), Marijuana Anonymous, or consultation with an addiction medicine specialist. These resources address cannabinoid use patterns regardless of the specific isomer involved.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most cannabinoid experiences, even uncomfortable ones, resolve without medical intervention. Seek immediate help if: chest pain or pounding heartbeat occurs, breathing becomes difficult, severe confusion or disorientation prevents communication, or the person becomes unresponsive.
Immediate steps:
- 1. Call emergency services if any of the above signs are present.
- 2. Keep the person calm, seated or lying in a comfortable position.
- 3. If unresponsive but breathing, place in the recovery position (on their side, mouth angled toward the ground).
- 4. Do not induce vomiting for orally consumed products.
- 5. Monitor breathing continuously until help arrives.
What to tell the dispatcher: Name the substance ("a cannabis product marketed as Delta-11 THC"), approximate amount consumed, time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during drug-related emergencies.
Legal Status[edit]
Δ-9,11-THC occupies a legal grey zone in most jurisdictions. As a positional isomer of Δ9-THC, it falls within broad cannabinoid scheduling provisions in many countries, though no jurisdiction has enacted legislation specifically naming it as of 2026.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Likely Schedule I (Controlled Substances Act) | The CSA controls "tetrahydrocannabinols" broadly, including "synthetic equivalents" and "isomers with similar chemical structure and pharmacological activity." The DEA has taken the position that synthetically derived THC compounds are Schedule I regardless of hemp origin.[12] Approximately 18 states have specifically restricted novel THC isomers. |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | THC isomers including Δ-9,11-THC are controlled under the "cannabinol derivatives" provision. |
| Canada | Controlled (Cannabis Act, 2018) | Cannabis derivatives including THC isomers are regulated. Production and sale require Health Canada licensing. |
| Australia | Controlled (TGA scheduling) | Cannabinoids require TGA scheduling approval for therapeutic use. Not available for unregulated consumer use. |
| European Union | Not formally notified (EWS) | Δ-9,11-THC has not been formally notified through the EU Early Warning System as of 2024. Individual member states' national legislation controlling THC isomers would typically apply.[8] |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current laws before possession, purchase, or use.
Drug testing
Δ-9,11-THC shows 25% cross-reactivity with standard immunoassay cannabinoid screening at 10–100 ng/mL.[13] A positive screen is possible after use. Confirmatory testing calibrated for Δ9-THC metabolites would likely return negative, as Δ-9,11-THC produces different metabolites.[13] Forensic laboratories require mass spectrometry methods specifically programmed for this compound.[4]
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- No data
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- 3 weeks
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Negligible
- Dose escalation
- Low
- Cross-tol.
- Δ9-THC · Δ8-THC · other CB1 agonists
Toxicity
Acute toxicity
No controlled toxicity data exist for Δ-9,11-THC in humans. No lethal dose has been published for any species, and no case reports of human adverse events attributable to the compound have been identified.safety citation needed
Δ-9,11-THC produced lethality in mice at doses higher than those required for Δ9-THC — qualitatively similar toxicity but with reduced potency.[2] No therapeutic index can be calculated from available data.
Cardiovascular effects
In anesthetized rats, Δ-9,11-THC reduced blood pressure approximately 8-fold less potently than Δ9-THC and potentiated epinephrine-induced blood pressure spikes and irregular heart rhythms not observed with vehicle alone.[6] The authors concluded that "both cannabinoids have adverse effects on the cardiovascular system and adverse interactions with epinephrine".[6] These findings have not been replicated in humans.safety citation needed
Product safety
As a semi-synthetic compound sold in an unregulated market, Δ-9,11-THC products carry risks beyond the compound's own pharmacology. Commercial semi-synthetic cannabinoid preparations contain multiple coexisting cannabinoids.[5] Consumers cannot assume product purity, accurate labeling, or absence of synthesis byproducts.
Psychological risks
No human data exist on psychological risks specific to Δ-9,11-THC. If the compound produces psychoactive effects (unconfirmed), the risk profile would resemble that of other CB1 agonists — including acute anxiety, paranoia, and transient psychotic symptoms at high doses — but attenuated in proportion to reduced potency.inferred
The nomenclature confusion with 11-OH-THC presents an indirect risk: users who believe they are consuming a compound "3× stronger than Δ9-THC" may dose aggressively expecting high potency, or may be unprepared for the actual effects.
Tolerance and dependence
No data exist on tolerance, cross-tolerance, physical dependence, psychological dependence, or withdrawal for Δ-9,11-THC. Given the compound's weak CB1 activity, abuse liability is expected to be lower than that of Δ9-THC, but this is structural inference without direct evidence.inferred
Drug Interactions
Sympathomimetics / epinephrine: Adverse cardiovascular interactions between Δ-9,11-THC and epinephrine have been documented in anesthetized rats — potentiation of blood pressure effects and induction of irregular heart rhythms.[6] Whether this extends to human sympathomimetic use is unknown but warrants caution.
Δ9-THC: The interaction is complex and species-dependent. In rhesus monkeys, pretreatment with Δ-9,11-THC attenuated Δ9-THC effects, suggesting functional antagonism. In mice and dogs, pretreatment enhanced Δ9-THC effects.[2] The clinical implication for human co-use is unknown.
CYP-mediated interactions: No enzyme inhibition or induction data exist for Δ-9,11-THC. Similar interactions to Δ9-THC are plausible but unconfirmed.inferred
Contraindications
4 knownNo substance-specific contraindication data exist. The following are inferred from class-level cannabinoid pharmacology and limited animal datainferred:
- Cardiovascular conditions: The epinephrine-potentiating effect documented in rats[6] suggests particular caution in individuals with pre-existing heart conditions, irregular heart rhythm, or concurrent use of sympathomimetic medications.
- Psychotic disorders: CB1 agonism is associated with precipitation and worsening of psychotic symptoms. Although Δ-9,11-THC's CB1 activity is weak, the risk cannot be excluded.
- Pregnancy and lactation: No reproductive toxicity data exist. Cannabinoids as a class cross the placental barrier and are excreted in breast milk.
Harm Reduction[edit]
Forms & Identification
Δ-9,11-THC is sold exclusively as a semi-synthetic product — vape cartridges, gummies, and tinctures produced by isomerizing hemp-derived CBD. No standardized pharmaceutical preparation exists. Because the compound is produced in unregulated facilities, the primary identification challenge is verifying that what is labeled "Delta-11 THC" actually contains Δ-9,11-THC rather than other cannabinoids or synthesis byproducts.
Standard cannabinoid reagent tests do not distinguish between THC isomers. Mass spectrometry is the only reliable method for confirming compound identity.[5] If third-party testing results are not available from the manufacturer, the contents should be considered unverified.
Guidelines
- Start with the smallest available dose and wait at least two hours before redosing — onset and duration are uncharacterized.
- Do not rely on marketing potency claims. Assertions that Δ-11-THC is "3× stronger than Δ9-THC" are unsupported and likely reflect confusion with a different compound.
- Avoid combining with other cannabinoids, alcohol, or sedatives until individual response is understood.
- Do not drive or operate machinery.
- Purchase only from manufacturers who provide third-party certificates of analysis showing cannabinoid composition and contaminant testing.
Set & Setting
Given the near-complete absence of human data, anyone choosing to use Δ-9,11-THC products should treat the experience as an encounter with an unknown compound. A familiar, comfortable environment and the presence of an unimpaired companion are prudent. Effects, if any, are expected to resemble mild cannabinoid intoxication, but product composition is unpredictable.
Aftercare & integration. Δ-9,11-THC is not expected to produce experiences requiring formal integration. If unexpected or uncomfortable effects occurred — particularly anxiety or confusion — allow adequate rest, hydrate, eat light meals, and avoid additional substance use for at least 24 hours. If distressing psychological effects persist beyond a day, consult a healthcare professional.
Recovery & Support
No dependence syndrome has been documented for Δ-9,11-THC specifically. Individuals concerned about patterns of cannabinoid use more broadly may benefit from SAMHSA's National Helpline (1-800-662-4357), Marijuana Anonymous, or consultation with an addiction medicine specialist. These resources address cannabinoid use patterns regardless of the specific isomer involved.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most cannabinoid experiences, even uncomfortable ones, resolve without medical intervention. Seek immediate help if: chest pain or pounding heartbeat occurs, breathing becomes difficult, severe confusion or disorientation prevents communication, or the person becomes unresponsive.
Immediate steps:
- 1. Call emergency services if any of the above signs are present.
- 2. Keep the person calm, seated or lying in a comfortable position.
- 3. If unresponsive but breathing, place in the recovery position (on their side, mouth angled toward the ground).
- 4. Do not induce vomiting for orally consumed products.
- 5. Monitor breathing continuously until help arrives.
What to tell the dispatcher: Name the substance ("a cannabis product marketed as Delta-11 THC"), approximate amount consumed, time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during drug-related emergencies.
Legal Status[edit]
Δ-9,11-THC occupies a legal grey zone in most jurisdictions. As a positional isomer of Δ9-THC, it falls within the scope of broad cannabinoid scheduling provisions in many countries. Its semi-synthetic production from hemp-derived CBD — legalized in the United States by the 2018 Farm Bill — creates regulatory ambiguity in jurisdictions that distinguish between "natural" and "synthetic" cannabinoids. No jurisdiction has enacted legislation specifically naming Δ-9,11-THC as of 2026.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Likely Schedule I (Controlled Substances Act) | The CSA controls "tetrahydrocannabinols" broadly, including "synthetic equivalents" and "isomers with similar chemical structure and pharmacological activity." The DEA has taken the position that synthetically derived THC compounds are Schedule I regardless of hemp origin.[12] Approximately 18 states have specifically restricted novel THC isomers. |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | THC isomers including Δ-9,11-THC are controlled under the "cannabinol derivatives" provision. |
| Canada | Controlled (Cannabis Act, 2018) | Cannabis derivatives including THC isomers are regulated. Production and sale require Health Canada licensing. |
| Australia | Controlled (TGA scheduling) | Cannabinoids require TGA scheduling approval for therapeutic use. Not available for unregulated consumer use. |
| European Union | Not formally notified (EWS) | Δ-9,11-THC has not been formally notified through the EU Early Warning System as of 2024. Individual member states' national legislation controlling THC isomers would typically apply.[9] |
Drug testing
Δ-9,11-THC shows 25% cross-reactivity with standard immunoassay-based cannabinoid screening at 10–100 ng/mL concentrations.[13] Workplace or clinical THC tests may return positive results after consumption. Confirmatory testing calibrated for the standard Δ9-THC metabolite would likely be negative, as Δ-9,11-THC produces different metabolites.[13] Forensic laboratories require mass spectrometry methods specifically programmed for this compound.[5]
Frequently asked questions
What is Δ-11-Tetrahydrocannabinol?
Δ-11-Tetrahydrocannabinol is a trace cannabinoid and structural isomer of Δ9-THC with an exocyclic double bond at C9–C11. It acts as a weak CB1 partial agonist in rodents but shows negligible cannabimimetic activity in primates; no human pharmacological data exist.
Where can I find dosage information for Δ-11-Tetrahydrocannabinol?
Psychedex publishes a dosage table for Δ-11-Tetrahydrocannabinol on this page covering these routes of administration: oral, inhaled. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Δ-11-Tetrahydrocannabinol?
The highest-severity documented interactions for Δ-11-Tetrahydrocannabinol: GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous), Ketamine, DXM, PCP (Dangerous), Local anesthetics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Δ-11-Tetrahydrocannabinol addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Δ-11-Tetrahydrocannabinol: tolerance builds slow; full reset takes 3 weeks; cross-tolerance develops with Δ9-THC, Δ8-THC, other CB1 agonists. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdKriwacki RW, Makriyannis A (1989) The conformational analysis of delta 9- and delta 9,11-tetrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy. — Molecular pharmacology PMID:2539557
- [2] ^abcPitt CG, Wildes JW, Martin NH, Wall ME (1971) Synthesis of (-)-Δ9(11)-trans-tetrahydrocannabinol — The Journal of Organic Chemistry doi:10.1021/jo00804a024
- [3] ^abcdReggio PH, Greer KV, Cox SM (1989) The importance of the orientation of the C9 substituent to cannabinoid activity — Journal of Medicinal Chemistry PMID:2738895
- [4] ^abcdeZhang S, Alam MM, Chandler BD, Lanorio JP, Deskins C, Song L (2025) Potency Analysis of Semi-Synthetic Cannabinoids in Vaping Oils Using Liquid Chromatography Diode Array Detector with Electrospray Ionization Time-of-Flight Mass Spectrometry for Confirmation of Analyte Identity. — Molecules (Basel, Switzerland) doi:10.3390/molecules30122597
- [5]
- [6] ^Wildes JW, Martin NH, Pitt CG, Wall ME (1971) The synthesis of (-)-delta-9(11)-trans-tetrahydrocannabinol. — The Journal of organic chemistry PMID:5545571
references
- [1] ^abcdKriwacki RW, Makriyannis A (1989) The conformational analysis of delta 9- and delta 9,11-tetrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy. — Molecular pharmacology PMID:2539557
- [2]
- [3] ^abcPitt CG, Wildes JW, Martin NH, Wall ME (1971) Synthesis of (-)-Δ9(11)-trans-tetrahydrocannabinol — The Journal of Organic Chemistry doi:10.1021/jo00804a024
- [4] ^abcdReggio PH, Greer KV, Cox SM (1989) The importance of the orientation of the C9 substituent to cannabinoid activity — Journal of Medicinal Chemistry PMID:2738895
- [5] ^abcdefZhang S, Alam MM, Chandler BD, Lanorio JP, Deskins C, Song L (2025) Potency Analysis of Semi-Synthetic Cannabinoids in Vaping Oils Using Liquid Chromatography Diode Array Detector with Electrospray Ionization Time-of-Flight Mass Spectrometry for Confirmation of Analyte Identity. — Molecules (Basel, Switzerland) doi:10.3390/molecules30122597
- [6]